Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 2/20 | 0.39 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.39 |
| ▸ | PDE1C | Q14123 | 1/20 | 0.33 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.33 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | KCNK3 | O14649 | 2/20 | 0.33 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.33 |
| ▸ | TERT | O14746 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | RET | P07949 | 1/20 | 0.31 |
| ▸ | CHRNB4 | P30926 | 1/20 | 0.31 |
| ▸ | CHRNA3 | P32297 | 1/20 | 0.31 |
| ▸ | CHRNA2 | Q15822 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8300882 | 0.83 | CHRNB2 (0.38) | CHRNB2CHRNA4PDE1CDDB1CRBN | |
| SCHEMBL2501141 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4ALDH1A1CHRNB4CHRNA3 | |
| SCHEMBL2501139 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4ALDH1A1CHRNB4CHRNA3 | |
| SCHEMBL2493562 | 0.77 | CHRNB2 (0.43) | CHRNB2CHRNA4DDB1CRBNCHRNB4 | |
| SCHEMBL2496717 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4PDE1CDDB1CRBN | |
| SCHEMBL2496720 | 0.76 | CHRNB2 (0.43) | CHRNB2CHRNA4PDE1CDDB1CRBN | |
| SCHEMBL2500351 | 0.72 | CHRNB2 (0.43) | CHRNB2CHRNA4PDE1CDDB1CRBN | |
| SCHEMBL2500349 | 0.72 | CHRNB2 (0.43) | CHRNB2CHRNA4PDE1CDDB1CRBN | |
| SCHEMBL2497733 | 0.72 | CHRNB2 (0.43) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 | |
| SCHEMBL12190738 | 0.71 | CHRNB2 (0.42) | CHRNB2CHRNA4CHRNB4CHRNA3CHRNA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8030300-B2 | 2-pyrrolidinyloxy-substituted pyridine; Alzheimer's disease, Parkinson's disease, dyskinesias, Tourette's syndrome, schizophrenia, attention deficit disorder, anxiety, pain, depression, obsessive compulsive disorder | GEORGETOWN UNIVERSITY (US) | 2011-10-04 | — | — | US | disclosed |
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | GEORGETOWN UNIVERSITY (US) | 2008-06-05 | — | — | US | disclosed |
| WO-2005000806-A2 | LIGANDS FOR NICOTINIC ACETYLCHOLINE RECEPTORS, AND METHODS OF MAKING AND USING THEM | GEORGETOWN UNIVERSITY (US) | 2005-01-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080132486-A1 | Ligands for Nicotinic Acetylcholine Receptors, and Methods of Making and Using Them | CHRNA5, OPRL1, TAAR5 | CHRNB2 36/4885CHRNA4 4/4885PDE1C 658/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.